DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/d11e48/kidney_cancer_pi) has announced the addition of Global Markets Direct's new report "Kidney Cancer - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Kidney Cancer - Pipeline Review, H1 2012', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Key Topics Covered:
- Introduction
- Global Markets Direct Report Coverage
- Kidney Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Kidney Cancer
- Kidney Cancer Therapeutics under Development by Companies
- Kidney Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Kidney Cancer Therapeutics - Products under Development by Companies
- Kidney Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Kidney Cancer Therapeutics Development
- Kidney Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Kidney Cancer Therapeutics - Drug Profile Updates
- Kidney Cancer Therapeutics - Discontinued Products
- Kidney Cancer Therapeutics - Dormant Products
- Kidney Cancer - Product Development Milestones
- Featured News & Press Releases
Companies Mentioned:
- Bristol-Myers Squibb Company, H1 2012
- Genzyme Corporation, H1 2012
- Boehringer Ingelheim GmbH, H1 2012
- F. Hoffmann-La Roche Ltd., H1 2012
- Kyowa Hakko Kirin Co., Ltd., H1 2012
- Amgen Inc., H1 2012
- AstraZeneca PLC, H1 2012
- Eli Lilly and Company, H1 2012
- GlaxoSmithKline plc, H1 2012
- Seattle Genetics, Inc., H1 2012
- Genentech, Inc., H1 2012
- Merck & Co., Inc., H1 2012
- Emergent BioSolutions Inc., H1 2012
- Oxford BioMedica plc, H1 2012
- Light Sciences Oncology, Inc., H1 2012
- Novartis AG, H1 2012
- ImClone Systems Incorporated, H1 2012
- Astellas Pharma Inc., H1 2012
- Eisai Co., Ltd., H1 2012
- Ono Pharmaceutical Co., Ltd., H1 2012
- OSI Pharmaceuticals, Inc., H1 2012
- Pfizer Inc., H1 2012
- Taiho Pharmaceutical Co., Ltd., H1 2012
- Exelixis, Inc., H1 2012
- Alfacell Corporation, H1 2012
- Celgene Corporation, H1 2012
- Bayer AG, H1 2012
- MannKind Corporation, H1 2012
- 3SBio Inc., H1 2012
- EntreMed, Inc., H1 2012
- Celldex Therapeutics, Inc., H1 2012
- Active Biotech AB, H1 2012
- AEterna Zentaris Inc., H1 2012
- AIDA Pharmaceuticals, Inc., H1 2012
- Lorus Therapeutics Inc, H1 2012
- Bionomics Limited, H1 2012
- Northwest Biotherapeutics, Inc., H1 2012
- Cleveland BioLabs, Inc., H1 2012
- Patrys Limited, H1 2012
- Keryx Biopharmaceuticals, Inc., H1 2012
- ARQULE, INC, H1 2012
- Allos Therapeutics, Inc, H1 2012
- Flamel Technologies S.A., H1 2012
- Dendreon Corporation, H1 2012
- Green Cross Corporation, H1 2012
- MOLOGEN AG, H1 2012
- OncoTherapy Science, Inc., H1 2012
- Threshold Pharmaceuticals, Inc., H1 2012
- Innate Pharma SA, H1 2012
- Protox Therapeutics Inc., H1 2012
- Rexahn Pharmaceuticals, Inc., H1 2012
- Debiopharm Group, H1 2012
- Antisense Pharma GmbH, H1 2012
- Wilex AG, H1 2012
- Philogen S.p.A., H1 2012
- Cadila Pharmaceuticals Ltd., H1 2012
- ERYtech Pharma, H1 2012
- immatics biotechnologies GmbH, H1 2012
- Curacyte AG, H1 2012
- Argos Therapeutics, Inc., H1 2012
- Cytheris SA, H1 2012
- Altor BioScience Corporation, H1 2012
- AgrenVec, S.L., H1 2012
- Alethia Biotherapeutics Inc., H1 2012
- Gene Signal International SA., H1 2012
- MacroGenics, Inc., H1 2012
- Pivotal BioSciences, Inc., H1 2012
- Neotropix, Inc., H1 2012
- Jennerex Biotherapeutics, Inc., H1 2012
- Endocyte, Inc., H1 2012
- Advenchen Laboratories, LLC, H1 2012
- Immutep S.A., H1 2012
- Syndax Pharmaceuticals, Inc., H1 2012
- Esperance Pharmaceuticals, Inc., H1 2012
- Welichem Biotech Inc., H1 2012
- Tigris Pharmaceuticals, Inc., H1 2012
- AVEO Pharmaceuticals, Inc., H1 2012
- KAHR medical Ltd., H1 2012
- Advanced Cancer Therapeutics, H1 2012
- Medical Enzymes AG, H1 2012
- IkerChem S.L., H1 2012
For more information visit http://www.researchandmarkets.com/research/d11e48/kidney_cancer_pi